



Continuous Increase of Cardiovascular Diseases, Diabetes, and Non-HIV Related Cancers as Causes of Death in HIV-Infected Individuals in Brazil: An Analysis of Nationwide Data

Adelzon A. Paula¹, Mauro Schechter², Suely H. Tuboi³, José Claudio Faulhaber⁴, Paula M. Luz⁵, Valdiléa G. Veloso⁵, Ronaldo I. Moreira⁵, Beatriz Grinsztejn⁵, Lee H. Harrison⁶, Antonio G. Pacheco^{1*}

1 Programa de Computação Científica, Fundação Oswaldo Cruz, Rio de Janeiro, Brasil, **2** Projeto Praça Onze, Hospital Escola São Francisco de Assis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brasil, **3** GlaxoSmithKline, Rio de Janeiro, Brasil, **4** Instituto de Matemática e Estatística, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brasil, **5** Instituto de Pesquisa Clínica Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brasil, **6** Infectious Diseases Epidemiology Research Unit, Graduate School of Public Health and School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America

Abstract

Introduction: After antiretroviral therapy (ART) became available, there was a decline in the number of deaths in persons infected with HIV. Thereafter, there was a decrease in the proportion of deaths attributed to opportunistic infections and an increase in the proportion of deaths attributed to chronic comorbidities. Herein we extend previous observations from a nationwide survey on temporal trends in causes of death in HIV-infected patients in Brazil.

Methods: We describe temporal trends in causes of death among adults who had HIV/AIDS listed in the death certificate to those who did not. All death certificates issued in Brazil from 1999 to 2011 and listed in the national mortality database were included. Generalized linear mixed-effects logistic models were used to study temporal trends in proportions.

Results: In the HIV-infected population, there was an annual adjusted average increase of 6.0%, 12.0%, 4.0% and 4.1% for cancer, external causes, cardiovascular diseases (CVD) and diabetes mellitus (DM), respectively, compared to 3.0%, 4.0%, 1.0% and 3.9%, in the non-HIV group. For tuberculosis (TB), there was an adjusted average increase of 0.3%/year and a decrease of 3.0%/year in the HIV and the non-HIV groups, respectively. Compared to 1999, the odds ratio (OR) for cancer, external causes, CVD, DM, or TB in the HIV group were, respectively, 2.31, 4.17, 1.76, 2.27 and 1.02, while for the non-HIV group, the corresponding OR were 1.31, 1.63, 1.14, 1.62 and 0.67. Interactions between year as a continuous or categorical variable and HIV were significant ($p < 0.001$) for all conditions, except for DM when year was considered as a continuous variable ($p = 0.76$).

Conclusions: Non HIV-related co-morbidities continue to increase more rapidly as causes of death among HIV-infected individuals than in those without HIV infection, highlighting the need for targeting prevention measures and surveillance for chronic diseases among those patients.

Citation: Paula AA, Schechter M, Tuboi SH, Faulhaber JC, Luz PM, et al. (2014) Continuous Increase of Cardiovascular Diseases, Diabetes, and Non-HIV Related Cancers as Causes of Death in HIV-Infected Individuals in Brazil: An Analysis of Nationwide Data. PLoS ONE 9(4): e94636. doi:10.1371/journal.pone.0094636

Editor: Jason F. Okulicz, Infectious Disease Service, United States of America

Received: December 3, 2013; **Accepted:** March 18, 2014; **Published:** April 11, 2014

Copyright: © 2014 Paula et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro/FAPERJ (www.faperj.br); Conselho Nacional de Desenvolvimento Científico e Tecnológico/CNPq (www.cnpq.br) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior/Capes (www.capes.gov.br). GlaxoSmithKline Group provided support in the form of a salary for author SHT (for part of the duration of this study), but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: BG is a PLOS ONE Editorial Board member. SHT was an employee of GlaxoSmithKline Group for part of the duration of this study. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: apacheco@fiocruz.br

Introduction

The widespread availability of ART led to an initial abrupt decrease in mortality in individuals infected with HIV, which leveled off in most countries after a few years [1–3]. Although causes of death traditionally associated with HIV/AIDS continue to play a prominent role, other conditions, including cardiovascular diseases (CVD), diabetes mellitus (DM), and cancer emerged as frequent causes of death [4–8]. In 1996, Brazil became the first

developing country to provide free and universal access to ART. We have previously described an increase in causes of death due to conditions generally not associated with HIV infection in Brazil at the local, regional, and national levels [1,4,9]. The aim of the present study was to expand our previous analyses of national temporal trends in selected non-AIDS-related causes of death and TB in persons with HIV infection.

Methods

In Brazil, the death certificate (DC) is a standardized form that is entered into a national electronic database, which is available online without personal identifiers (http://tabnet.datasus.gov.br/tabdata/sim/dados/cid10_indice.htm). Primary, secondary, and contributing causes of death according to the International Classification of Diseases 10th revision (ICD-10) codes are available for all deaths that occurred since 1999.

We compared temporal trends in causes of death for individuals who had HIV/AIDS listed in any field of the DC (ICD-10 codes B20-B24, Z21-[HIV group]) and for those who did not have HIV/AIDS mentioned (non-HIV group). Logistic regression models were fitted with generalized linear mixed-effects models (GLMM) equations. Statistical methods are described elsewhere [9]. Briefly, year of death was treated either as a continuous or categorical variable in the models. In the former case, linear trends are reported as the average variation per year, while in the latter odds ratios (ORs) are used to compare annual changes relative to the baseline year of 1999. Statistical significance was assessed through differences in slopes in temporal trends testing the interaction term between HIV status and year. We conducted five separate analyses in which the outcomes were defined by the presence or absence in any field of the DC of non-HIV-related cancers, external causes, CVD, DM and tuberculosis (Table 1). All analyses were performed in R for Windows 3.0.2 (<http://www.r-project.org>), using the package 'lme4' for GLMM estimation.

Results

A total of 12,366,853 deaths were reported among adults 18 years of age or older between 1999 and 2011. Of these, 151,706 (1.23%) had HIV/AIDS reported in any field of the DC. Mean age at death (annual increment) for the HIV and non-HIV groups were 41.6 (0.39) years and 66.9 (0.16) years, respectively; the annual increment during the study period was significantly higher for the HIV group ($p < 0.001$).

The adjusted average increases for non-HIV related cancers were 6.0% (95%CI = 1.05–1.07; $p < 0.001$) and 3.0% (95%CI = 1.02–1.03; $p < 0.001$) per year in the HIV and non-HIV groups, respectively. Compared to 1999, the ORs for having non-HIV related cancers listed on the DC in 2011 were 2.31 (95%CI = 1.92–2.77; $p < 0.001$) for the HIV group and 1.31 (95%CI = 1.22–1.40; $p < 0.001$) for the non-HIV group (Figure 1A).

For external causes, there were adjusted average increases of 12.0% (95%CI = 1.09–1.15; $p < 0.001$) and 4.0% (95%CI = 1.04–1.05; $p < 0.001$) per year in the HIV and non-HIV groups,

respectively. In comparison to 1999, the ORs for having external causes mentioned on the DC in 2011 were 4.17 (95%CI = 2.97–5.85; $p < 0.001$) and 1.63 (95%CI = 1.53–1.72; $p < 0.01$) for the HIV and non-HIV groups, respectively (Figure 1B).

The adjusted average increases for CVD were 4.0% (95%CI = –1.03–1.05; $p < 0.001$) and 1.0% (95%CI = –1.00–1.02; $p < 0.001$) per year in the HIV and non-HIV groups, respectively. Compared to 1999, the ORs for having CVD listed on the DC in 2011 were 1.76 (95%CI = 1.56–1.98; $p < 0.001$) and 1.14 (95%CI = 1.09–1.20; $p < 0.001$) for the HIV and non-HIV groups, respectively (Figure 1C).

DM had adjusted annual increases of 4.1% (95%CI = 1.02–1.06; $p < 0.001$) and 3.9% (95%CI = 1.03–1.04; $p < 0.001$) per year in the HIV and non-HIV groups, respectively. Compared to 1999, the ORs for having DM listed on the DC in 2011 were 2.27 (95%CI = 1.70–3.02; $p < 0.001$) for the HIV group and 1.62 (95%CI = 1.54–1.70; $p < 0.001$) for the non-HIV group (Figure 1D).

In contrast, for TB there was an adjusted average increase of 0.3% (95%CI = 1.00–1.01; $p = 0.42$) per year in the HIV group and a 3.0% decrease (95%CI = 0.97–0.978; $p < 0.001$) for the non-HIV group. Compared to 1999, the ORs for having TB listed on the DC in 2011 were 1.02 (95%CI = 0.93–1.12; $p = 0.66$) and 0.67 (95%CI = 0.62–0.73; $p < 0.001$) per year for the HIV and non-HIV groups, respectively (Figure 1E).

Interactions between year as a continuous or a categorical variable and HIV were both significant ($p < 0.001$) for all conditions except for DM when year was considered as a continuous variable ($p = 0.76$).

Discussion

We were among the first to describe the emergence of non-HIV related conditions as important causes of death in HIV-infected individuals in a developing country setting [1,4,9]. We now describe a continuous and significant increase in the proportion of non-AIDS related conditions as causes of death in HIV-infected persons from 1999 to 2011. DM, CVD, non-HIV related cancers, and external causes increased significantly more in the HIV group than in the non-HIV group. In contrast, there was a sustained decrease of TB as a cause of death in the non-HIV population, while remaining virtually unchanged in the HIV group. The latter is in keeping with reports from developed and developing country settings, where TB remains an important cause of morbidity and mortality in HIV-infected individuals [6,10,11].

Changes in patterns of causes of death in HIV infected individuals are mostly ascribed to the widespread availability of ART [12–14]. Although effective use of ART is associated with

Table 1. Definition of groups of disease and ICD-10 codes used in this study.

Disease/group	ICD-10 code	Comments
HIV group	B20-B24, Z21	Not all codes that mention HIV make sense in this context, so Z11.4 was not included among other codes.
Non-AIDS-related cancers	C00-C97 (except C46 and C80-C89)	Excludes Kaposi's sarcoma, immunoblastic lymphoma, Burkitt's lymphoma, and primary brain lymphoma.
External causes	S00-Y98	Includes violent causes, accidents, non-fatal trauma, poisoning and drug abuse.
Cardiovascular diseases	I00-I99 except I46	Excludes cardiac arrest (not a real cause of death).
Diabetes mellitus	E10-E14	
Tuberculosis	A15-A19	

doi:10.1371/journal.pone.0094636.t001




Figure 1. Odds ratios and 95% confidence intervals comparing the chance of having the disease listed on the death certificate over time of Non-HIV related cancers (A), external causes (B), cardiovascular diseases (C), Diabetes Mellitus (D) and Tuberculosis (E); year as a categorical variable and 1999 as the baseline reference.
doi:10.1371/journal.pone.0094636.g001

decreased incidence of conditions associated with advanced immune deficiency, a significant number of successfully treated individuals remain in a pro-inflammatory state, which in turn has been associated with non-AIDS related conditions, particularly CVD [15,16].

There are data documenting a global increase of CVD in the HIV-infected population [1,9,17]. It is assumed that the prevalence of CVD is higher among age-matched HIV-infected individuals as a result of a complex interplay between a higher frequency of well-established risk factors, HIV-related inflammatory and immunologic changes, and the adverse effects of certain antiretroviral drugs. Smoking, the most important risk factor for CVD and lung cancer, is more common in HIV-infected individuals than in the general population [17] and may explain our findings at least partially.

As life expectancy increases among people living with HIV/AIDS, a growing number of individuals are at risk of co-morbid conditions that typically occur at older ages, including cancers and DM [5,18,19]. As an example, we have recently reported an increase in the incidence of both non-HIV and HIV-related cancers in HIV-infected in Rio de Janeiro, with lung cancer leading the former group [4]. Given the relatively high prevalence of co-infections with hepatitis B and C viruses in Brazil [20], one can expect an increasing importance of hepatic cancers as a cause of morbidity and mortality as HIV individual live longer. The significantly faster growth of external causes as causes of death in the HIV-infected population, which may be partially attributed to life style [21], is a matter that we believe deserves further investigation.

In Brazil, as elsewhere, the metabolic syndrome is increasingly common in HIV infected individuals and may play an important role in the faster growth of DM and DCV as causes of death in the HIV infected population in comparison to the general population [22].

It should be noted that our findings cannot be attributed to faster aging of the HIV-infected population alone. Even though the mean age of death in the general population increased less than the mean age of death in the HIV group (0.24% vs. 0.94% per year), all the models used were controlled for age. Moreover, it has been estimated that in Brazil two thirds of the HIV-infected individuals who died in the post-HAART era were aged 30 to 49 years [23].

A major strength of our study is that we analyzed all DC issued nationwide for a period spanning over one decade. Another

strength is the use of any mention of conditions on the DC, which overcomes one of the limitations of the current ICD system, which does not cover some diseases associated with HIV.

Our study has several limitations, since we analyzed data from DC, which may lack sensitivity and specificity for certain medical conditions. Nonetheless, by using a strategy that is commonly utilized in studies that investigate occupational hazards, we were able to estimate the odds ratios by comparing individuals who had HIV/AIDS cited in their DC to those who did not. As is the case for all population-based studies, particularly those involving only death certificates data, we cannot rule out the influence of unmeasured confounders potentially associated with non-HIV associated causes of death, including smoking habits and hepatitis B and/or C serostatus. Nonetheless, we have previously reported a significant underreporting of HIV/AIDS as a cause of death in individuals known to be HIV-infected in Rio de Janeiro [24]. Predictors of underreporting included male gender, older age, and higher CD4 counts, all of which are associated with CVD and DM.

Conclusions

The continuous increase in the frequency of non-AIDS related causes of death described in the present study might become an even greater burden for health systems as the HIV-infected population ages. On the other hand, some of these conditions, particularly CVD, DM, and lung cancer, can be prevented or effectively managed by public health interventions, such as smoking cessation and lipids, glucose, an blood pressure control. Given the potential role played by unmeasured confounders, further studies are necessary to address and elucidate the results present herein. Finally, despite the availability of effective preventative interventions, TB remains a major cause of death among HIV-infected patients. Its prevention should be a major focus of public health interventions, including wider use of isoniazid primary prophylaxis when indicated.

Author Contributions

Conceived and designed the experiments: MS AGP. Performed the experiments: AAP AGP. Analyzed the data: AAP MS SHT JCF PML VGV RIM BG LHH AGP. Contributed reagents/materials/analysis tools: AGP. Wrote the paper: AAP MS AGP. Interpreted, discussed and suggested adjustments in the analysis: AAP MS SHT JCF PML VGV RIM BG LHH AGP.

References

- Pacheco AG, Tuboi SH, May SB, Moreira LFS, Ramadas L, et al. (2009) Temporal changes in causes of death among HIV-infected patients in the HAART era in Rio de Janeiro, Brazil. *J Acquir Immune Defic Syndr* 51: 624–630.
- Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boule A, et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. *Lancet* 367: 817–824.
- Lee SH, Kim KH, Lee SG, Chen DH, Jung DS, et al. (2013) Trends of Mortality and Cause of Death among HIV-Infected Patients in Korea, 1990–2011. *J Korean Med Sci* 28: 67–73.
- Grinsztejn B, Luz PM, Pacheco AG, Santos DV, Velasque L, et al. (2013) Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era. *PLoS ONE* 8: e59768.
- Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, et al. (2011) Cancer burden in the HIV-infected population in the United States. *J Natl Cancer Inst* 103: 753–762.
- Pacheco AG, Durovni B, Cavalcante SC, Lauria LM, Moore RD, et al. (2008) AIDS-related tuberculosis in Rio de Janeiro, Brazil. *PLoS ONE* 3: e3132.
- Crum NF, Riffenburgh RH, Wegner S, Agan BK, Tasker SA, et al. (2006) Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. *J Acquir Immune Defic Syndr* 41: 194–200.
- Stewart A, Chan Carusone S, To K, Schaefer-McDaniel N, Halman M, et al. (2012) Causes of Death in HIV Patients and the Evolution of an AIDS Hospice: 1988–2008. *AIDS Res Treat* 2012: 390406.
- Pacheco AG, Tuboi SH, Faulhaber JC, Harrison LH, Schechter M (2008) Increase in non-AIDS related conditions as causes of death among HIV-infected individuals in the HAART era in Brazil. *PLoS ONE* 3: e1531.
- Antiretroviral Therapy in Low-Income Countries Collaboration of the International epidemiological Databases to Evaluate A, Collaboration ARTC, Brinkhof MW, Egger M, Boule A, et al. (2007) Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. *Clin Infect Dis* 45: 1518–1521.
- Cortes CP, Wehbe FH, McGowan CC, Shepherd BE, Duda SN, et al. (2013) Duration of Anti-Tuberculosis Therapy and Timing of Antiretroviral Therapy Initiation: Association with Mortality in HIV-Related Tuberculosis. *PLoS One* 8: e74057.
- Lewden C, Salmon D, Morlat P, Bevilacqua S, Jouglu E, et al. (2005) Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. *Int J Epidemiol* 34: 121–130.
- Palella FJ Jr., Baker RK, Moorman AC, Chmiel JS, Wood KC, et al. (2006) Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of

- Death and Disease in the HIV Outpatient Study. *J Acquir Immune Defic Syndr* 43: 27–34.
14. Yang CH, Huang YF, Hsiao CF, Yeh YL, Liou HR, et al. (2008) Trends of mortality and causes of death among HIV-infected patients in Taiwan, 1984–2005. *HIV Med* 9: 535–543.
 15. Duprez DA, Neuhaus J, Kuller LH, Tracy R, Bellosso W, et al. (2012) Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. *PLoS ONE* 7: e44454.
 16. Deeks SG, Lewin SR, Havlir DV (2013) The end of AIDS: HIV infection as a chronic disease. *Lancet* 382: 1525–1533.
 17. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, et al. (2003) Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study. *Aids* 17: 1179–1193.
 18. Justice AC (2010) HIV and aging: time for a new paradigm. *Curr HIV/AIDS Rep* 7: 69–76.
 19. Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, et al. (2012) Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. *J Int AIDS Soc* 15: 17426.
 20. Wolff FH, Fuchs SC, Barcellos NN, de Alencastro PR, Ikeda ML, et al. (2010) Co-infection by hepatitis C virus in HIV-infected patients in southern Brazil: genotype distribution and clinical correlates. *PLoS ONE* 5: e10494.
 21. Antiretroviral Therapy Cohort C (2010) Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. *Clin Infect Dis* 50: 1387–1396.
 22. Paula AA, Falcao MC, Pacheco AG (2013) Metabolic syndrome in HIV-infected individuals: underlying mechanisms and epidemiological aspects. *AIDS Res Ther* 10: 32.
 23. Rezende EL, Vasconcelos AM, Pereira MG (2010) Causes of death among people living with HIV/AIDS in Brazil. *Braz J Infect Dis* 14: 558–563.
 24. Pacheco AG, Saraceni V, Tuboi SH, Lauria LM, Moulton LH, et al. (2011) Estimating the extent of underreporting of mortality among HIV-infected individuals in Rio de Janeiro, Brazil. *AIDS Res Hum Retroviruses* 27: 25–28.